Immunotherapeutic vaccines - Aastrom/Duke University

Drug Profile

Immunotherapeutic vaccines - Aastrom/Duke University

Alternative Names: Immunotherapeutic vaccines - Aastrom/Duke University

Latest Information Update: 18 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aastrom Biosciences; Duke University Medical Center
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastrointestinal cancer

Most Recent Events

  • 18 May 2006 Discontinued - Phase-I for Gastrointestinal cancer in USA (unspecified route)
  • 15 Dec 2003 Phase-I clinical trials in Gastrointestinal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top